Absence of IgA and growth hormone deficiency associated with short arm deletion of chromosome 18.
38
Citation
7
Reference
10
Related Paper
Citation Trend
Keywords:
Long arm
Long arm
Abnormality
Chromosome abnormality
Refractory (planetary science)
Chromosomal Abnormality
Cite
Citations (436)
Adult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life. Daily subcutaneous injections with recombinant growth hormone (GH) can alleviate the abnormalities associated with AGHD. Several long-acting GH (LAGH) preparations are currently in development that aim to reduce treatment burden for patients receiving daily GH injections. Somapacitan (Sogroya ® ; Novo Nordisk, Denmark) is the first LAGH preparation that has been approved for treatment of AGHD in the United States, Europe, and Japan. The recent approval of somapacitan and anticipated approval of other LAGH molecules presents new questions for physicians planning to treat AGHD with LAGH in the future. Differences in the technologies used to prolong the half-life of recombinant GH are expected to result in variations in pharmacokinetic and pharmacodynamic profiles between preparations. Therefore, it is essential that physicians understand and consider such variations when treating patients with these novel GH replacement therapies. Here, we present a set of treatment recommendations that have been created to guide physicians initiating therapy with somapacitan in patients with AGHD who are eligible for GH replacement. Furthermore, we will review the published data that underlie these recommendations to explain the rationale for the treatment and monitoring advice provided.
Pharmacodynamics
Cite
Citations (9)
An acrotrisomic plant was isolated in the progeny of the primary trisomic for chromosome 4. It was designated as acrotrisomic 4L4S. Five marker stocks were crossed as male to the acrotrisomic 4L4S. The F2 segregation in the trisomic tests showed that the gene i, previously located in the distal part of the long arm, segregated in a disomic ratio, indicating that i is located on the missing segment of the long arm. The genes lk5, gs1 and yh in the short arm also segregated in a disomic ratio, indicating their locations should be in the deficient part of the short arm of chromosome 4. The gene f10 on the short arm showed a trisomic ratio, indicating that this gene is located on the remaining proximal segment of the short arm. Acrosomic trisomic analysis provide, a valuable approach for physical localization of genes on barley chromosomes.
Long arm
Chromosome 3
Cite
Citations (1)
Hintz RL. Final height of growth hormone‐treated patients with growth hormone deficiency: the North American experience. Acta Pædiatr 1999; Suppl 428: 70–1. Stockholm. ISSN 0803–5326 The results of treatment of growth hormone (GH)‐deficient patients with recombinant GH are better than the results of treatment with pituitary GH. The reasons for this improvement include higher dosages, more consistent treatment, and daily administration. Under ideal circumstances, final height in patients with GH deficiency (GHD) can be within the normal range for adult height with GH treatment, and brought close to their target height. To achieve this result, it is important to diagnose and treat GHD early, use adequate doses of GH, and continue treatment until final height. □ Growth hormone, growth hormone deficiency, final height
Dose
Growth hormone treatment
Human growth hormone
Cite
Citations (14)
IGHD
Cite
Citations (0)
The main goal of growth hormone (GH)-replacement therapy for adults with growth hormone deficiency is to achieve physiologic re' placement. GH secretion varies from day to day and depends on a number of factors including age, sex, body composition, and sleep patterns. This variability means that GH dosage must be individualized and adjusted in response to efficacy and safety outcomes. The efficacy of GH-replacement therapy can be monitored by assessing changes in body composition or in levels of GH-related peptides. In addition, patients should be monitored for the occurrence of adverse events.
Cite
Citations (7)
Objective . To describe a biochemical growth hormone (GH) deficiency and to evaluate therapeutic result in a six-year-old male with Becker muscular dystrophy (BMD). Methods . GH peak was evaluated after response to arginine and insulin. Bone age was evaluated according to Greulich and Pyle method. Results . The GH-supplementary therapy was very effective in terms of growth gain. Conclusion . The possibility of a growth hormone deficiency and treatment with GH in patients with BMD cannot be excluded, especially considering the good therapeutic response.
Therapeutic effect
Cite
Citations (3)
Idiopathic short stature
Growth hormone treatment
Cite
Citations (1)
Growth hormone treatment
Idiopathic short stature
Cite
Citations (0)
Growth hormone treatment
Cite
Citations (5)